Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alios Biopharma IncfiledCriticalAlios Biopharma Inc
Publication of AR110675A1publicationCriticalpatent/AR110675A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Se describen oligonucleótidos modificados que comprenden modificaciones en las posiciones 2’ y/o 3’ en conjunto con métodos para laborarlas y usos, por ejemplo, contra HBV. Reivindicación 1: Un oligonucleótido que comprende uno o más nucleótidos de la fórmula (1), en donde R es H o un contraión con carga positiva; B es una nucleobase; R¹ es -(CR’₂)₂OCR’₃; y R’ es independientemente en cada caso H o F. Reivindicación 104: Un método para inhibir la replicación de un virus en una célula; el método comprende poner en contacto la célula con un oligonucleótido o con una composición que comprende el oligonucleótido de cualquiera de las reivindicaciones 1 a 97, en donde el oligonucleótido contiene una secuencia de nucleobases que es complementaria o se híbrida con una porción de un ARN objetivo viral.Modified oligonucleotides are described which comprise modifications in the 2 ’and / or 3’ positions in conjunction with methods for working them and uses, for example, against HBV. Claim 1: An oligonucleotide comprising one or more nucleotides of the formula (1), wherein R is H or a positively charged counterion; B is a nucleobase; R¹ is - (CR’₂) ₂OCR’₃; and R ’is independently in each case H or F. Claim 104: A method of inhibiting the replication of a virus in a cell; The method comprises contacting the cell with an oligonucleotide or with a composition comprising the oligonucleotide of any one of claims 1 to 97, wherein the oligonucleotide contains a nucleobase sequence that is complementary or hybridizes with a portion of a target RNA. viral.
ARP170102544A2016-09-142017-09-14
MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE
AR110675A1
(en)
Compounds derived from nucleosides substituted in 4’-azido, 3’-fluoro or their salts, as inhibitors of vhc rna replication; pharmaceutical composition that includes them; and its use for the treatment or prophylaxis of hepatitis C virus (vhc) infection.